

Accepted Manuscript

The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529

Xujun Hu, Zirui Wang, Meikai Chen, Xuerong Chen, Wenqing Liang

PII: S0006-291X(18)30273-0

DOI: [10.1016/j.bbrc.2018.02.050](https://doi.org/10.1016/j.bbrc.2018.02.050)

Reference: YBBRC 39415

To appear in: *Biochemical and Biophysical Research Communications*

Received Date: 2 February 2018

Accepted Date: 6 February 2018

Please cite this article as: X. Hu, Z. Wang, M. Chen, X. Chen, W. Liang, The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529, *Biochemical and Biophysical Research Communications* (2018), doi: 10.1016/j.bbrc.2018.02.050.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529

Xujun Hu ^{1#}, Zirui Wang ^{2#}, Meikai Chen ¹, Xuerong Chen ¹, and Wenqing Liang ^{1*}

¹ Department of Orthopaedics, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China

² East Medical area, Internal medicine ward, Linyi People's Hospital, Linyi City, Shandong, China

Co-first authors

* Corresponding author. Dr. Wenqing Liang, Department of Orthopaedics, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, 568 Zhongxing North Road, Shaoxing 312000, Zhejiang Province, China. Tel: +86-575-88229063, Fax: +86-575-88229063. Email: liangwqgk9@163.com.

Abstract. mTOR over-activation is important for human osteosarcoma (OS) tumorigenesis and progression. RES-529 is a mTORC1/2 dual inhibitor. Here, our results show that RES-529 inhibited viability, cell cycle progression and proliferation of the established (U2OS line) and primary human OS cells. RES-529 induced apoptosis activation in OS cells. It was yet non-cytotoxic to OB-6 osteoblastic cells and the primary human osteoblasts. RES-529 disrupted assembling of mTORC1 (mTOR-Raptor association) and mTORC2 (mTOR-Rictor-mLST8 association) in human OS cells, blocking mTORC1/2 activation. Significantly, RES-529 induced reactive oxygen species (ROS) production and mitochondrial depolarization in U2OS cells as well. RES-529-induced anti-OS cell activity was more potent than other known Akt-mTOR inhibitors. *In vivo*, RES-529 intraperitoneal injection significantly inhibited U2OS xenograft tumor growth in severe combined immunodeficiency (SCID) mice. mTORC1/2 activation in RES-529-treated tumor tissues was largely inhibited. Collectively, the mTOR inhibitor RES-529 efficiently inhibits human OS cell growth *in vitro* and *in vivo*.

Keywords. Osteosarcoma; mTOR; RES-529; Akt and Molecularly-targeted therapy.

Download English Version:

<https://daneshyari.com/en/article/8293925>

Download Persian Version:

<https://daneshyari.com/article/8293925>

[Daneshyari.com](https://daneshyari.com)